Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors

Sep 13 2016

• By Emily Hayes

Related Content

New Interleukin Inhibitors May Give <em>Stelara</em> A Run For The Psoriasis Money

Mar 30 2015

Pfizer/Celltrion Prep For October Inflectra Launch

Aug 23 2016

FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx

Mar 23 2016

Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No

Jul 19 2016

New Data Bolsters Cosentyx In AS & PsA; Humira Head-To-Head Planned

Jun 08 2016

CVS Indication-Based Pricing For Cancer Drugs May Roll Out Later In 2016

Mar 04 2016

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Jul 19 2016

Payer Briefs: Express Scripts Pricing Pilot; HHS Risk Adjustment; Value Frameworks

Apr 01 2016

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

Aug 31 2016

Related Companies

Express Scripts Holding Company

Novartis AG

AbbVie Inc.

Amgen, Inc.

Johnson & Johnson

Eli Lilly and Company

AbbVie Inc.

UCB S.A.

CVS Health Corp.

Novartis AG

Pfizer Inc.

Celltrion, Inc.

Additional Topics

Reimbursement Strategy Commercial Immune Disorders Inflammation BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window